Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

New Zealand's Auckland emerges from lockdown, Australia starts AstraZeneca vaccinations

Published 03/06/2021, 06:47 PM
Updated 03/06/2021, 10:25 PM
© Reuters. FILE PHOTO: People jog past a social distancing sign in Auckland, New Zealand, August 31, 2020

By Lidia Kelly

MELBOURNE (Reuters) - Auckland, New Zealand's biggest city, emerged on Sunday from a strict weeklong lockdown imposed after a community cluster of the more contagious British coronavirus variant.

There were no new local COVID-19 cases recorded on Sunday, health officials said, marking a full week of no community transmissions across the country.

Footage on TVNZ, New Zealand's state-owned television network, showed people lining up at coffee shops on Sunday morning with many saying they were feeling relieved.

Auckland, a city of nearly two million, will continue to have limits on public gathering and masks are obligatory on public transport. Restrictions might be further eased on Friday.

Neighbouring Australia also had no local COVID-19 cases on Sunday, making it the 37th day of no infections this year. There have been no related deaths in 2021.

Swift public health measures combined with aggressive contact tracing, border closures and compulsory quarantine for travellers have been credited with making New Zealand and Australia highly successful in keeping the pandemic from spreading.

Both countries saw their economies recovering speedily in the second part of 2020. Australia's economy expanded at a much faster-than-expected pace in the final quarter of last year and all signs were that 2021 has started on a firm footing too.

Coronavirus inoculation began in both countries, with the vaccination rollout in Australia becoming slightly complicated after Italy blocked a shipment of the AstraZeneca (NASDAQ:AZN)'s vaccine.

Australia's Health Minister Greg Hunt, among the first receive the University of Oxford/AstraZeneca vaccine on Sunday after an earlier shipment, said the rollout is on track.

Inoculation with the Pfizer/BioNTech vaccine started in February, but most Australians will be vaccinated with the University of Oxford/AstraZeneca vaccine.

The weekly number of administered doses is expected to reach 1 million by the end of March when CSL (OTC:CSLLY) Ltd begins to locally produce 50 million of the AstraZeneca doses.

The government is spending more than AUD6 billion ($4.6 billion) to support the vaccine rollout with contracts for over 150 million doses of various COVID-19 vaccines.

© Reuters. FILE PHOTO: A rainbow appears on the Auckland skyline featuring Sky Tower in New Zealand

($1 = 1.3011 Australian dollars)

Latest comments

Yeh.. Over reaction as more targeted quarantine measures to be implemented to avoid disruptions to lives and economy...
Again, fake news.People never said they are relieved, they said they are angry and annoyed at all the nonsense
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.